{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:41:52Z","timestamp":1789753312072,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04494-0","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T09:05:35Z","timestamp":1755075935000},"page":"1481-1496","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Consideration of the biosimilar drug lag and loss among Japan, the USA, and the EU"],"prefix":"10.1007","volume":"399","author":[{"given":"Aya","family":"Hariu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Saino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6778-7114","authenticated-orcid":false,"given":"Ryosuke","family":"Kuribayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"4494_CR1","unstructured":"ASPE. Competition in prescription drug markets, 2017\u20132022. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/1aa9c46b849246ea53f2d69825a32ac8\/competition-prescription-drug-markets.pdf Accessed 27 Jun 2025."},{"key":"4494_CR2","unstructured":"Biosimilars Council. Biosimilar medicines saved $12.4 billion in 2023. 2024. https:\/\/biosimilarscouncil.org\/news\/biosimilar-medicines-saved-12-4-billion\/ Accessed 31 Dec 2024."},{"key":"4494_CR3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1080\/13696998.2024.2379212","volume":"27","author":"K Clarke","year":"2024","unstructured":"Clarke K, Ainslie-Garcia M, Ferko N, Shastri K (2024) Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective. J Med Econ 27:952\u2013962. https:\/\/doi.org\/10.1080\/13696998.2024.2379212","journal-title":"J Med Econ"},{"key":"4494_CR4","unstructured":"EMA. Concept paper for the development of a reflection paper on a tailored clinical approach in biosimilar development (2023)\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/other\/concept-paper-development-reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf . Accessed 31 Dec 2024"},{"key":"4494_CR5","unstructured":"EMA. EMA website for search medicines for human use. https:\/\/www.ema.europa.eu\/en\/medicines Accessed 27 Jun 2025."},{"key":"4494_CR6","unstructured":"EMA. Biosimilar medicines: overview. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/biosimilar-medicines-overview Accessed 27 Jun 2025."},{"key":"4494_CR7","unstructured":"EMA. Guideline on similar biological medicinal products. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-first-version_en.pdf Accessed 27 Jun 2025."},{"key":"4494_CR8","unstructured":"EMA. Multidisciplinary: biosimilar. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/multidisciplinary-guidelines\/multidisciplinary-biosimilar Accessed 27 Jun 2025."},{"key":"4494_CR9","unstructured":"Fuji Keizai Group. No. 22060. https:\/\/www.fuji-keizai.co.jp\/press\/detail.html?cid=22060&view_type=2&la=ja Accessed 27 Feb 2025 (In Japanese)."},{"key":"4494_CR10","unstructured":"GaBI. Russian approval for non-originator Dornase alfa. https:\/\/www.gabionline.net\/biosimilars\/news\/Russian-approval-for-non-originator-dornase-alfa Accessed 31 Dec 2024."},{"key":"4494_CR11","unstructured":"GaBI. Biosimilars of certolizumab pegol. https:\/\/www.gabionline.net\/biosimilars\/general\/Biosimilars-of-certolizumab-pegol Accessed 31 Dec 2024."},{"key":"4494_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1208\/s12248-025-01091-0","volume":"27","author":"A Hariu","year":"2025","unstructured":"Hariu A, Shirahata Y, Shinohara K, Kuribayashi R (2025) The 100th monoclonal antibody product is approved in Japan. AAPS J 27:105. https:\/\/doi.org\/10.1208\/s12248-025-01091-0","journal-title":"AAPS J"},{"issue":"4","key":"4494_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/1073110519898043","volume":"47","author":"Y Heled","year":"2019","unstructured":"Heled Y (2019) The case for disclosure of biologics manufacturing information. J Law Med Ethics 47(4):54\u201378. https:\/\/doi.org\/10.1177\/1073110519898043","journal-title":"J Law Med Ethics"},{"key":"4494_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/clpt.2009.215","volume":"87","author":"Y Hirai","year":"2010","unstructured":"Hirai Y, Kinoshita H, Kusama M, Yasuda K, Sugiyama Y, Ono S (2010) Delays in new drug applications in Japan and industrial R&D strategies. Clin Pharmacol Ther 87:212\u2013218. https:\/\/doi.org\/10.1038\/clpt.2009.215","journal-title":"Clin Pharmacol Ther"},{"key":"4494_CR15","unstructured":"ICH E17. General principles for planning and design of multiregional clinical trials. 2017. https:\/\/www.pmda.go.jp\/files\/000224562.pdf Accessed 3 Jul 2025."},{"key":"4494_CR16","unstructured":"IQVIA. The impact of biosimilar competition in Europe. 2023. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2023.pdf Accessed 30 Dec 2024."},{"key":"4494_CR17","unstructured":"IQVIA. Biosimilars in the United States 2023\u20132027. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/biosimilars-in-the-united-states-2023-2027\/iqvia-institute-biosimilars-in-the-united-states-2023-usl-orb3393.pdf Accessed 27 Feb 2025."},{"key":"4494_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312577","volume":"19","author":"H Itoshima","year":"2024","unstructured":"Itoshima H, Takada D, Goto E, Sasaki N, Kunisawa S, Imanaka Y (2024) The impact of financial incentives promoting biosimilar products in oncology: a quasi-experimental study using administrative data. PLoS One 19. https:\/\/doi.org\/10.1371\/journal.pone.0312577","journal-title":"PLoS One"},{"key":"4494_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/14712598.2024.2377300","volume":"24","author":"R Kuribayashi","year":"2024","unstructured":"Kuribayashi R, Goto K, Hariu A, Kishioka Y (2024) Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan. Expert Opin Biol Ther 24:637\u2013645. https:\/\/doi.org\/10.1080\/14712598.2024.2377300","journal-title":"Expert Opin Biol Ther"},{"key":"4494_CR20","doi-asserted-by":"publisher","unstructured":"Mehr\u00a0SR (2024) Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it. J Manag Care Spec Pharm 30:600\u20133. https:\/\/doi.org\/10.18553\/jmcp.2024.30.6.600","DOI":"10.18553\/jmcp.2024.30.6.600"},{"key":"4494_CR21","unstructured":"McKinsey & Company. Three imperatives for R&D in biosimilars. 2022. https:\/\/www.mckinsey.com\/industries\/life-sciences\/our-insights\/three-imperatives-for-r-and-d-in-biosimilars Accessed 31 Dec 2024."},{"key":"4494_CR22","unstructured":"MHLW. Basic principles on global clinical trials. 2007. https:\/\/www.pmda.go.jp\/files\/000153265.pdf Accessed 3 Jul 2025."},{"key":"4494_CR23","unstructured":"MHLW. Basic principles on global clinical trials (ReferenceCases). 2012. https:\/\/www.pmda.go.jp\/files\/000157520.pdf Accessed 3 Jul 2025."},{"key":"4494_CR24","unstructured":"MHLW. Guideline for ensuring quality, safety, and efficacy of biosimilars. 2020. https:\/\/www.pmda.go.jp\/files\/000267479.pdf Accessed 27 Feb 2025."},{"key":"4494_CR25","unstructured":"MHLW. Basic principles for conducting phase 1 studies in Japanese prior to initiating multi-regional clinical trials including Japan for drugs in which early clinical development is preceding outside Japan. 2023. https:\/\/www.pmda.go.jp\/files\/000266727.pdf Accessed 21 Dec 2024."},{"key":"4494_CR26","unstructured":"MHLW. Q & A for \u201cPlanning of the pediatric drug development program during development of drugs for adults\u201d. 2024. https:\/\/www.pmda.go.jp\/files\/000268524.pdf Accessed 21 Dec 2024."},{"key":"4494_CR27","unstructured":"MHLW. Q&A for basic principles for conducting phase 1 studies in Japanese prior to initiating multi-regional clinical trials including Japan for drugs in which early clinical development is preceding outside Japan. https:\/\/www.pmda.go.jp\/files\/000266728.pdf Accessed 21 Dec 2024."},{"key":"4494_CR28","unstructured":"MHLW. Partial revision of \u201cDesignation of orphan drugs etc.\u201d 2024. https:\/\/www.pmda.go.jp\/files\/000268408.pdf Accessed 21 Dec 2024."},{"key":"4494_CR29","unstructured":"MHLW. Questions and answers (Q&A) for designation of orphan drugs etc. 2024. https:\/\/www.pmda.go.jp\/files\/000268407.pdf Accessed 21 Dec 2024."},{"key":"4494_CR30","unstructured":"MHLW. Partial revision of \u201cPlanning of the pediatric drug development program during development of drugs for adults\u201d. 2024. https:\/\/www.pmda.go.jp\/files\/000268523.pdf Accessed 21 Dec 2024."},{"key":"4494_CR31","unstructured":"MHLW. Questions and answers (Q&A) on guideline for ensuring the quality, safety, and efficacy of biosimilars. 2024. https:\/\/www.pmda.go.jp\/files\/000267480.pdf Accessed 31 Dec 2024."},{"key":"4494_CR32","unstructured":"MHLW. Questions and answers (Q&A) on guideline for ensuring the quality, safety, and efficacy of biosimilars. https:\/\/www.pmda.go.jp\/files\/000267480.pdf Accessed 27 Jun 2025."},{"key":"4494_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamainternmed.2020.3997","volume":"181","author":"TJ Moore","year":"2021","unstructured":"Moore TJ, Mouslim MC, Blunt JL, Alexander GC, Shermock KM (2021) Assessment of availability, clinical testing, and US Food and Drug Administration review of biosimilar biologic products. JAMA Intern Med 181:52\u201360. https:\/\/doi.org\/10.1001\/jamainternmed.2020.3997","journal-title":"JAMA Intern Med"},{"issue":"1","key":"4494_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1743517","volume":"12","author":"E Moorkens","year":"2020","unstructured":"Moorkens E et al (2020) An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry? Mabs 12(1). https:\/\/doi.org\/10.1080\/19420862.2020.1743517","journal-title":"Mabs"},{"issue":"3","key":"4494_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ymgme.2020.04.003","volume":"130","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Kawashima S, Tozawa H, Yamaoka M, Yamamoto T, Tanaka N, Yamamoto R, Okuyama T, Eto Y (2020) Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: phase I and II\/III clinical studies. Mol Genet Metab 130(3):215\u2013224. https:\/\/doi.org\/10.1016\/j.ymgme.2020.04.003","journal-title":"Mol Genet Metab"},{"key":"4494_CR36","unstructured":"Nippon. Japan\u2019s senior population falls for the first time on record. https:\/\/www.nippon.com\/en\/japan-data\/h01796\/ Accessed 27 Feb 2025."},{"key":"4494_CR37","unstructured":"OECD. Health at a glance 2023. https:\/\/www.oecd.org\/en\/publications\/health-at-a-glance-2023_7a7afb35-en.html Accessed 27 Feb 2025."},{"key":"4494_CR38","doi-asserted-by":"publisher","unstructured":"Oura M, Saito H, Nishikawa Y. Shortage of Nab-paclitaxel in Japan and around the world: issues in global information sharing. JMA J. 2023;6:192\u201395. https:\/\/doi.org\/10.31662\/jmaj.2022-0179","DOI":"10.31662\/jmaj.2022-0179"},{"key":"4494_CR39","unstructured":"PMDA. Review report for Agalcidaze beta BS IV Infusion [JCR]. 2018. https:\/\/www.pmda.go.jp\/drugs\/2018\/P20181017002\/530210000_23000AMX00804000_A100_1.pdf (In Japanese). Accessed 30 Dec 2024."},{"key":"4494_CR40","unstructured":"PMDA. PMDA website for biosimilars. https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/0005.html Accessed 21 Dec 2024."},{"key":"4494_CR41","unstructured":"Press Release: ICH Assembly Meeting, Madrid, Spain, May 2025. https:\/\/ich.org\/pressrelease\/press-release-ich-assembly-meeting-madrid-spain-may-2025 Accessed 27 Jun 2025."},{"issue":"1","key":"4494_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41587-020-00780-9","volume":"39","author":"AK Rai","year":"2021","unstructured":"Rai AK, Price WN (2021) An administrative fix for manufacturing process patent thickets. Nat Biotechnol 39(1):20\u201322. https:\/\/doi.org\/10.1038\/s41587-020-00780-9","journal-title":"Nat Biotechnol"},{"key":"4494_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2019.104525","volume":"110","author":"AS Rathore","year":"2020","unstructured":"Rathore AS, Bhargava A (2020) Biosimilars in developed economies: overview, status, and regulatory considerations. Regul Toxicol Pharmacol 110. https:\/\/doi.org\/10.1016\/j.yrtph.2019.104525","journal-title":"Regul Toxicol Pharmacol"},{"key":"4494_CR44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/d41573-021-00045-3","volume":"20","author":"K Sakushima","year":"2021","unstructured":"Sakushima K, Takeda H, Aoi Y (2021) Orphan drug designation and development in Japan: 25 years of experience and assessment. Nat Rev Drug Discov 20:893\u2013894. https:\/\/doi.org\/10.1038\/d41573-021-00045-3","journal-title":"Nat Rev Drug Discov"},{"key":"4494_CR45","unstructured":"Tanaka D. Regulatory updates in Japan. 2024. https:\/\/www.pmda.go.jp\/files\/000269411.pdf Accessed 21 Dec 2024."},{"key":"#cr-split#-4494_CR46.1","unstructured":"The Japan News (2024) Japanese government to lower hurdles for new drug applications"},{"key":"#cr-split#-4494_CR46.2","unstructured":"aims to improve Japan's 'drug loss' problem. https:\/\/japannews.yomiuri.co.jp\/society\/general-news\/20240429-183065\/ . Accessed 2 Jan 2025"},{"key":"4494_CR47","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1365-2710.2009.01099.x","volume":"35","author":"K Tsuji","year":"2010","unstructured":"Tsuji K, Tsutani K (2010) Approval of new drugs 1999\u20132007: comparison of the US, the EU and Japan situations. J Clin Pharm Ther 35:289\u2013301. https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01099.x","journal-title":"J Clin Pharm Ther"},{"key":"4494_CR48","unstructured":"U.S. FDA. Somatropin. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2006\/021426s000LTR.pdf Accessed 27 Jun 2025."},{"key":"4494_CR49","unstructured":"U.S. FDA. Teriparatide. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2024\/218771Orig1s000ltr.pdf Accessed 27 Jun 2025."},{"key":"4494_CR50","unstructured":"U.S. FDA. Biosimilar product information. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information Accessed 21 Dec 2024."},{"key":"4494_CR51","unstructured":"U.S. FDA. A milestone in facilitating the development of safe and effective biosimilars. 2024. https:\/\/www.fda.gov\/news-events\/fda-voices\/milestone-facilitating-development-safe-and-effective-biosimilars Accessed 29 Dec 2024."},{"key":"4494_CR52","unstructured":"U.S. FDA. FDA approves first interchangeable biosimilar for two rare diseases. 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-interchangeable-biosimilar-two-rare-diseases Accessed 30 Dec 2024."},{"key":"4494_CR53","unstructured":"U.S. FDA. Considerations in demonstrating interchangeability with a reference product: update. 2024. https:\/\/www.fda.gov\/media\/179456\/download Accessed 31 Dec 2024."},{"key":"4494_CR54","unstructured":"U.S. FDA. Insulin lispro. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2017\/209196Orig1s000ltr.pdf Accessed 27 Jun 2025."},{"key":"4494_CR55","unstructured":"U.S. FDA. \u201cDeemed to be a license\u201d provision of the BPCI Act. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/deemed-be-license-provision-bpci-act Accessed 10 Jun 2025."},{"issue":"1","key":"4494_CR56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41587-021-01170-5","volume":"40","author":"VL Van de Wiele","year":"2022","unstructured":"Van de Wiele VL, Beall RF, Kesselheim AS, Sarpatwari A (2022) The characteristics of patents impacting availability of biosimilars. Nat Biotechnol 40(1):22\u201325. https:\/\/doi.org\/10.1038\/s41587-021-01170-5","journal-title":"Nat Biotechnol"},{"key":"4494_CR57","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1001\/jama.2024.16911","volume":"332","author":"OJ Wouters","year":"2024","unstructured":"Wouters OJ, Vogel M, Feldman WB, Beall RF, Kesselheim AS, Tu SS (2024) Differential legal protections for biologics vs small-molecule drugs in the US. JAMA 332:2101\u20132108. https:\/\/doi.org\/10.1001\/jama.2024.16911","journal-title":"JAMA"},{"key":"4494_CR58","unstructured":"Wu JCC (2020) Into the woods: a biologic patent thicket analysis. Chicago-Kent J Intellect Property 19(93). https:\/\/scholarship.kentlaw.iit.edu\/ckjip\/vol19\/iss1\/12\/"},{"key":"4494_CR59","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s40123-023-00715-y","volume":"12","author":"Y Yanagi","year":"2023","unstructured":"Yanagi Y, Takahashi K, Iida T, Gomi F, Morii J, Kunikane E, Sakamoto T (2023) Cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration in Japan. Ophthalmol Ther 12:2005\u20132021. https:\/\/doi.org\/10.1007\/s40123-023-00715-y","journal-title":"Ophthalmol Ther"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04494-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04494-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04494-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:03:07Z","timestamp":1771538587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04494-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4494"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04494-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The views expressed in this article are those of the authors and do not necessarily reflect the official views of the Pharmaceuticals and Medical Devices Agency.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}